Epithalon
A telomerase-activating peptide studied for anti-aging and longevity.
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide Epithalamin, produced by the pineal gland. Developed by Dr. Vladimir Khavinson, it is primarily studied for its ability to activate telomerase — the enzyme that rebuilds telomeres at the ends of chromosomes. Telomere shortening is a key marker of cellular aging, making Epithalon one of the most researched anti-aging peptides.
Key Benefits
Telomerase Activation
Directly stimulates telomerase activity, potentially slowing or reversing telomere shortening associated with cellular aging.
Pineal Gland Support
Restores melatonin production in the pineal gland, which declines significantly with age, supporting circadian rhythm regulation.
Antioxidant Enhancement
Increases antioxidant enzyme activity and reduces lipid oxidation, protecting cells from free radical damage.
Improved Sleep
By restoring melatonin production, Epithalon may improve sleep quality and normalize circadian rhythms in aging individuals.
Potential Lifespan Extension
Animal studies show significant lifespan extension in rodents treated with Epithalon — up to 24% in some models.
Cancer Resistance
Research in animal models suggests reduced spontaneous tumor incidence in Epithalon-treated groups compared to controls.
Research Dosing Information
Not FDA-approved. Cycling is the standard approach — short intensive cycles separated by months. Some protocols use 10 mg daily for 10 days, repeated every 4-6 months. Developed from decades of research at the St. Petersburg Institute of Bioregulation.
Research Summary
Epithalon research spans over 35 years under Dr. Khavinson and colleagues. Key findings include: activation of telomerase in human somatic cells, 24% lifespan extension in mice, reduced spontaneous tumor incidence in rats, and restoration of melatonin cycling in elderly patients. A clinical study in elderly patients showed improved physical endurance, circadian function, and reduced biological aging markers after Epithalon treatment. The peptide's mechanisms center on telomerase activation and pineal gland restoration.
Safety Considerations
- Not FDA-approved for any medical use.
- Well-tolerated in published clinical studies with no significant adverse effects.
- Long-term safety data in humans is limited despite decades of research.
- Theoretical concern: telomerase activation could theoretically promote cancer cell immortality — though research shows reduced tumor incidence.
- Quality of commercially available products varies.
Frequently Asked Questions
Does Epithalon really activate telomerase?
Yes. Multiple published studies demonstrate that Epithalon activates telomerase in human somatic cells. A 2003 study showed 2.4-fold telomerase activation in human fibroblasts and 1.6-fold in endothelial cells.
How often should Epithalon be cycled?
Common research protocols use 10-20 day intensive cycles repeated 2-3 times per year. Continuous daily use is not the standard approach — cycling appears to be more effective.
Can Epithalon cause cancer?
This is a common concern, but animal research actually shows reduced spontaneous tumor incidence in Epithalon-treated groups. However, the theoretical risk of promoting existing cancers through telomerase activation has not been fully ruled out.
Related Content
This page is for educational and research purposes only. It is not medical advice. Consult a healthcare professional before using any peptide or supplement. None of the statements on this page have been evaluated by the FDA.